Evidence map›Paper›PMID 24923251›Full record

ArticleBritish journal of pharmacology2015

Anti-nociception mediated by a κ opioid receptor agonist is blocked by a δ receptor agonist.

A M W Taylor, K W Roberts, A A Pradhan, H A Akbari, W Walwyn, K Lutfy, F I Carroll, C M Cahill, C J Evans

Open access · hybridAbstract read
In one paragraph

Article in British journal of pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Kappa Opioid Receptors Drive a Tonic Aversive Component of Chronic Pain.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2019
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

A M W TaylorUniversity of California, Los Angeles, CA, USA; University of California Irvine, Irvine, CA, USA.
K W Roberts
A A Pradhan
H A Akbari
W Walwyn
K Lutfy
F I Carroll
C M Cahill
C J Evans
University of California, Los Angeles · USUniversity of California, Irvine · USUniversity of Illinois Chicago · USRTI International · USWestern University of Health Sciences · US

Funding

The Role of Striosome Neurons in Mediating Opiod RewardP50DA005010 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FANSELOW, MICHAEL S · 1987 to 2021
$30.7M
Selective Opioid Antagonists as Medications for Drug AbuseR01DA009045 · NIDA · RESEARCH TRIANGLE INSTITUTE · PI CARROLL, FRANK IVY · 1994 to 2014
$5.6M
In Vivo Implications of Agonist Selective Activation of Delta Opioid ReceptorR00DA031243 · NIDA · UNIVERSITY OF ILLINOIS AT CHICAGO · PI PRADHAN, AMYNAH AMIR ALI · 2013 to 2015
$743k
In Vivo Implications of Agonist Selective Activation of Delta Opioid ReceptorK99DA031243 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PRADHAN, AMYNAH AMIR ALI · 2011 to 2012
$317k
NIDA NIH HHS DA005010NIDA NIH HHS DA031243NIDA NIH HHS K99 DA031243NIDA NIH HHS P50 DA005010NIDA NIH HHS R00 DA031243NIDA NIH HHS R01 DA009045
6 · The paper itself

Abstract

background and purposeThe opioid receptor family comprises four structurally homologous but functionally distinct sub-groups, the μ (MOP), δ (DOP), κ (KOP) and nociceptin (NOP) receptors. As most opioid agonists are selective but not specific, a broad spectrum of behaviours due to activation of different opioid receptors is expected. In this study, we examine whether other opioid receptor systems influenced KOP-mediated antinociception. EXPERIMENTAL APPROACH: We used a tail withdrawal assay in C57Bl/6 mice to assay the antinociceptive effect of systemically administered opioid agonists with varying selectivity at KOP receptors. Pharmacological and genetic approaches were used to analyse the interactions of the other opioid receptors in modulating KOP-mediated antinociception. KEY

resultsEtorphine, a potent agonist at all four opioid receptors, was not anti-nociceptive in MOP knockout (KO) mice, although etorphine is an efficacious KOP receptor agonist and specific KOP receptor agonists remain analgesic in MOP KO mice. As KOP receptor agonists are aversive, we considered KOP-mediated antinociception might be a form of stress-induced analgesia that is blocked by the anxiolytic effects of DOP receptor agonists. In support of this hypothesis, pretreatment with the DOP antagonist, naltrindole (10 mg·kg(-1) ), unmasked etorphine (3 mg·kg(-1) ) antinociception in MOP KO mice. Further, in wild-type mice, KOP-mediated antinociception by systemic U50,488H (10 mg·kg(-1) ) was blocked by pretreatment with the DOP agonist SNC80 (5 mg·kg(-1) ) and diazepam (1 mg·kg(-1) ). CONCLUSIONS AND IMPLICATIONS: Systemic DOP receptor agonists blocked systemic KOP antinociception, and these results identify DOP receptor agonists as potential agents for reversing stress-driven addictive and depressive behaviours mediated through KOP receptor activation. LINKED ARTICLES: This article is part of a themed section on Opioids: New Pathways to Functional Selectivity. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2015.172.issue-2.

Indexed as

3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-IsomerAnalgesiaAnalgesics, Non-NarcoticAnalgesics, OpioidAnimalsBehavior, AnimalBenzamidesDiazepamEtorphineFemaleHot TemperatureMaleMice, Inbred C57BLMice, KnockoutNaltrexoneNociceptin Receptor3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-N,N-diethylbenzamideAnalgesics, Non-NarcoticAnalgesics, OpioidBenzamidesDiazepamEtorphineNaltrexonenaltrindoleNociceptin ReceptorOprl1 protein, mousePiperazinesReceptors, OpioidReceptors, Opioid, deltaReceptors, Opioid, kappaReceptors, Opioid, mu

Identifiers

PMID24923251
PMCPMC4292979
OpenAlexW1580167736

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.